TABLE 2

Associations between APM1 variants and the risk of CVD in diabetic men

SNPCVD case subjectsControl subjectsOR (95% CI)
UnadjustedPAdjusted*P
−11365CC138 (59.5)333 (53.7)1.01.0
CG85 (36.6)243 (39.2)0.85 (0.62–1.16)0.310.90 (0.63–1.29)0.58
GG9 (3.9)44 (7.1)0.50 (0.24–1.05)0.060.55 (0.24–1.22)0.14
−4034AA104 (44.4)270 (43.1)1.01.0
AC101 (43.2)280 (44.7)0.94 (0.68–1.29)0.700.94 (0.66–1.35)0.76
CC29 (12.4)76 (12.1)0.99 (0.61–1.61)0.981.12 (0.64–1.95)0.68
−3964AA154 (66.1)426 (68.8)1.01.0
AG67 (28.8)165 (26.7)1.13 (0.81–1.59)0.461.24 (0.85–1.83)0.26
GG12 (5.1)28 (4.5)1.20 (0.59–2.41)0.610.98 (0.43–2.26)0.96
+45TT170 (77.6)440 (73.5)1.01.0
TG + GG49 (22.4)159 (26.5)0.80 (0.55–1.15)0.220.77 (0.51–1.16)0.21
+276GG105 (46.0)293 (49.3)1.01.0
GT111 (48.7)249 (41.9)1.30 (0.93–1.77)0.101.33 (0.94–1.89)0.11
TT12 (5.3)52 (8.8)0.67 (0.35–1.31)0.240.46 (0.22–0.97)0.04
TT vs. GG + GT0.58 (0.30–1.11)0.080.38 (0.18–0.79)0.009
  • Data are n (%) unless otherwise indicated.

  • *

    * ORs were estimated adjusting for age, BMI, smoking, alcohol consumption, physical activity, HbA1c, aspirin use, history of hypertension, and history of hypercholesterolemia.